Novotech
Founded 1997 · 2,173 employees on LinkedIn · 4 known investors
Novotech is a contract research organization (CRO) that provides clinical trial execution and scientific advisory services for biotech and biopharma sponsors, including complex cell and gene therapy trials. It has a strong regional focus on the Asia-Pacific market.
Also known as Novotech CRO · Novotech Group
Founders & leadership
Investors · 4
Company profile
researched Aug 2026Novotech is a full-service contract research organization (CRO) and scientific advisory company founded in 1997 that provides biotech and small- to mid-sized pharmaceutical sponsors with clinical development and trial execution services. Its service lines span medical and regulatory consulting, site selection, early-phase trials in Australia, clinical operations and project management, site management organization (SMO) services, biometrics and data management, real-world data, laboratory services, pharmacometrics, drug development consulting, GMO solutions, and clinical and regulatory strategy.
Therapeutic-area expertise marketed by the company includes oncology, liver disease, infectious diseases and vaccines, and orphan and rare diseases, with published content covering early-phase oncology, therapeutic radiopharmaceuticals, B-cell depletion in autoimmune disease, RNA development, obesity, idiopathic pulmonary fibrosis and hepatitis B. Novotech also produces disease landscape reports, white papers, webinars, podcasts and case studies as part of its thought-leadership program, including case studies on a U.S. sponsor's Phase III Parkinson's disease trial across Asia-Pacific, Phase I/II oncology start-up and recruitment in Australia, and first-in-human mRNA immunotherapy trials in APAC.
Third-party company profiles describe a global footprint of more than 30 offices across Asia-Pacific, North America and Europe and partnerships with more than 5,000 trial sites, and place headquarters variously in Sydney, Australia and in Singapore. In January 2026 the company appointed Anand Tharmaratnam as Chief Executive Officer.
Business model
Novotech operates as a services business, contracting with drug developers to plan and run clinical trials and to provide related regulatory, biometrics, laboratory and consulting support. Reported engagements include sponsor-specific CRO appointments, such as being selected by Marvel Biosciences as CRO for the Phase I trial of MB-204.
Traction
Third-party profiles report employment in the 1,001-5,000 range (approximately 2,100 employees as of July 2026), more than 5,000 trial site partnerships, and 19 consecutive years of Frost & Sullivan CRO Company of the Year recognition.
Latest developments
In January 2026 Novotech appointed Anand Tharmaratnam as CEO. Other recent activity includes a February 2026 multi-trial license with ObvioHealth for the ObvioGo digital trial platform, selection in March 2026 as CRO for Marvel Biosciences' Phase I trial of MB-204 in neurodevelopmental disorders, a partnership announced in June 2026 with The START Center for Cancer Research, recognition at the AustCham Korea Australia-Korea Business Awards in 2020 and 2026, and a December 2025 white paper on early-phase oncology strategy and execution. In August 2025 the company noted its support of the approval of an anlotinib combination therapy for advanced soft tissue sarcoma.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Novotech is positioned as a biotech-focused global CRO competing with large clinical research organizations such as IQVIA, Parexel, PPD, Medpace, Syneos Health, ICON, WuXi AppTec and Charles River Laboratories. It has been named Frost & Sullivan CRO Company of the Year for 19 consecutive years and was awarded 2025 Global Biotechnology Contract Research Organization Company of the Year by Frost & Sullivan.
Technology
The company uses digital trial delivery tooling, including a multi-trial license for ObvioHealth's ObvioGo platform to support digital and hybrid trial delivery, alongside analytical tools used to support patient recruitment and trial efficiency.
Go-to-market
The company markets through direct business development and an extensive content program of disease landscape reports, white papers, webinars, podcasts, case studies and conference participation, alongside partnerships with site networks and technology providers.
Biotech companies and small- to mid-sized pharmaceutical sponsors seeking clinical trial execution, with particular emphasis on sponsors running early-phase and multi-region programs in Asia-Pacific.
Geography
More than 30 offices across the Asia-Pacific region, North America and Europe, with access to over 5,000 trial sites. Corporate addresses reported include Level 3, 235 Pyrmont Street, Pyrmont, Sydney, NSW, Australia and 9 Raffles Place, Republic Plaza Level 52, Singapore. Press releases are issued from both Sydney and Singapore, and the website is offered in English, Korean, and simplified and traditional Chinese.
History
Novotech was established in 1997 and has grown into a global CRO with offices across Asia-Pacific, North America and Europe. Leadership changed in January 2026 with the appointment of Anand Tharmaratnam as Chief Executive Officer.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 8
launches, deals, and filingsNovotech partnered with The START Center for Cancer Research, an early-phase, community-based oncology site network operating across the US and Europe.
Novotech has been recognised twice at the AustCham Korea Australia-Korea Business Awards, in 2020 and 2026, in the Life Sciences and Healthcare category.
Novotech was awarded the 2025 Global Biotechnology Contract Research Organization Company of the Year by Frost & Sullivan.
Marvel Biosciences selected Novotech as CRO for its Phase I clinical trial of MB-204, evaluating the candidate in neurodevelopmental disorders including Rett syndrome and Fragile X, as well as autism spectrum disorder and depression.
Novotech selected ObvioGo under a multi-trial license to scale digital trial delivery.
Novotech announced from Singapore the appointment of Dr. Anand Tharmaratnam as its new CEO.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Novotechnovotech-cro.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Novotech do?
- Novotech is a full-service clinical research organization and scientific advisory firm serving biotech and small- to mid-cap pharma.
- Who are Novotech's investors?
- Novotech's investors include TPG, GIC, Temasek, Mercury Capital.